OFID signs grant agreement with King Hussein Cancer Foundation Zawya Thu, 03 Dec 2009 02:00 AM PST 01 December 2009 VIENNA -- The OPEC Fund for International Development (OFID) signed an agreement with the King Hussein Cancer Foundation (KHCF) worth USD 600,000 to purchase state-of-the-art equipment for the Center's Interventional Radiological Suite, as well as the construction and modification of the Suite to accommodate the new equipment. | Crowds mourn scholar's death The Daily Texan Thu, 03 Dec 2009 01:56 AM PST By: Alex Geiser Leslie Hope Jarmon, a former faculty development specialist and pioneer of virtual environments at UT, died Nov. 24 in her Austin home at the age of 57 after a 15-year-long fight against cancer.... | Govt working to reduce cancer drug prices: Jena Press Trust of India Thu, 03 Dec 2009 01:51 AM PST New Delhi, Dec 3 (PTI) Government today said it was working towards bringing 23 anti-cancer medicines under the Drug (Price Control) Order to lower their prices. | Louise Beaudet: A Passion For Animation Animation World Network Thu, 03 Dec 2009 01:48 AM PST On January 3, Louise Beaudet, perhaps the most famous and respected animation archivist in the world died of lung cancer. In her role as curator of Montréal's Cinémathèque Québecoise, she more than helped fulfill that organization's special interest in animation. | Thriving, not just surviving Park Hills Daily Journal Thu, 03 Dec 2009 01:46 AM PST Despite cancer, diabetes, bereavement and muscular dystrophy, St. Francois County residents are finding ways of not only surviving their challenges, but thriving. | Bonus culture called destructive, beyond repair Toronto Star Thu, 03 Dec 2009 01:44 AM PST I've long thought excessive CEO pay is the cancer eating away at sound corporate management. Excessive pay for top management distorts decision making. It encourages reckless and short-term behaviour that damages the enterprise and undermines the wider economy. | Press Release PharmiWeb Thu, 03 Dec 2009 01:40 AM PST Newbury 03 December 2009, Bayer Healthcare today submitted its appeal to NICE, contesting the instituteâs Final Appraisal Determination (FAD) to deny patients with advanced hepatocellular carcinoma (HCC), the commonest form of primary liver cancer, NHS funding for Nexavar® (sorafenib). | | |
|
No comments:
Post a Comment